In 2018, Harrisburg-based Life Sciences Greenhouse of Central Pennsylvania (LSGPA) invested $2.5 million in three Pennsylvania companies that potentially could significantly change healthcare in the future.
MacuLogix in Middletown was awarded slightly more than $1.2 million and soon will be moving to its new headquarters in Harrisburg. The company is developing a way to prevent blindness caused by age-related macular degeneration by providing eye care professionals with the education and tools to detect and manage the disease.
Micro Interventional Devices in Newtown was awarded $1 million for its 40-patient, multisite European trial of the company’s minimally invasive annuloplasty technology for tricuspid valve repair.
Ocunova, a spinout of the Penn State Hershey College of Medicine, received $250,000 for its development of a treatment for diabetic dry eye.
“LSGPA continues to seek out opportunities to invest in the region’s most promising startups and is equally proud of our reputation for nurturing and continuing to invest in worthy portfolio companies as they mature,” LSGPA President and CEO Mel Billingsley said.
Along with investments from other sources, the company netted $25 million.
LSGPA’s goal is to speed up the commercialization of life-sciences technologies through early-stage investment and business development services.